Canada· CA-DIN-00782505
APO-NADOLOL
A nadolol product containing nadolol, registered in Canada by APOTEX INC. The same ATC class is registered in 6 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Nadolol is registered in 6 of 19 countries.
Countries holding a registration under ATC C07AA12 (nadolol), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 3 of them publish a price we can compare per daily dose
Nadolol · ATC C07AA12
6 / 19 countries
- Canada
- Franceprice
- Japan
- Norwayprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nadolol costs, country by country.
Normalised to the WHO defined daily dose (0.16 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nadolol · price per daily dose (0.16 g)
USD · FX 28 Sept 2026
- FR France$0.84
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- NADOLOL
- Manufacturer
- APOTEX INC
- Country
- Canada (CA)
- ATC code
- C07AA12
- ATC class
- Nadolol
- Defined daily dose
- 0.16 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
302 interactions on record for nadolol.
Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nadolol · interactions on record
302 records
- 31 severe
- 164 moderate
- 28 minor
- 79 info
Most severe, free to view
- DolasetronA04AA04severe
- EpinephrineB02BC09severe
- EpinephrineC01CA24severe
- OrciprenalinC01CA29severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nadolol in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesNadololZydus Pharmaceuticals USA Inc.
- United KingdomCorgard 40mg tabletsSanofi-Synthelabo Ltd
- NorwayApo-NadololApotex
- FranceCORGARD 80 mg, comprimé sécableCHEPLAPHARM FRANCE
- Japanナドロール住友ファーマ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- France · Corgard
- United Kingdom (Northern Ireland) · Nadolol Neon Healthcare
- Italy · Nadololo Cheplapharm
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/43cdc7a3-b107-4b46-a2cf-b63220af61b4 GET /v1/drugs/43cdc7a3-b107-4b46-a2cf-b63220af61b4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "00782505",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "C07AA12",
"schedule": [
"Prescription"
],
"drug_code": "9178",
"strengths": [
"40 MG"
],
"ahfs_class": null,
"substances": [
"NADOLOL"
],
"product_categorization": null
}See everything about nadolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.